After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options.

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

Dupixent becomes the first-ever targeted therapy for patients with COPD, the first biologic for the disease, and the first new treatment approach in Europe in over a decade. It has been cleared ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

In September 2024, the FDA approved Dupixent for chronic obstructive pulmonary disease (COPD), marking its sixth indication and making it the first biologic approved for COPD. Dupixent is also ...

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

Robust Pipeline To Pump Out Future Growth Regeneron's top blockbuster drug, Dupixent, was recently approved by the FDA for COPD treatment. However, this approval occurred when REGN was in a downward ...

Most studies on COPD focus on an older cohort of participants, typically those 60 and older. By enrolling younger participants who are at risk of COPD, we hope to determine why some smokers ...